Journal
SCIENCE
Volume 330, Issue 6005, Pages 831-835Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1191175
Keywords
-
Categories
Funding
- NIH [CA98468, CA127231]
- UNC Chapel Hill
- Damon Runyon Cancer Research Foundation [CI15-02]
- Golden Leaf Foundation
- State of North Carolina
Ask authors/readers for more resources
The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial beta-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial beta-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial beta-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available